Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LM103 TILs in Advanced Melanoma
NCT07310784Phase 2Recruiting
- Sponsor
- Suzhou BlueHorse Therapeutics
- Start
- Dec 2025
- Primary completion
- Dec 2027
- Modality
- Tumor-Infiltrating Lymphocytes (TILs)
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of LM103 in melanoma (2 arms), sponsored by Suzhou BlueHorse Therapeutics. Primary endpoint: Progression-Free Survival at 104 weeks. Started Dec 2025; status: recruiting.
02
Drugs
LM103
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT07310784.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07310784.